USA, Germany & France all updated prostate cancer guidance to include genetic testing for all metastatic and also high-risk cases
UK NICE has not updated its prostate guidance NG131 since 2021 - not planning to do so for another 18 months
The current UK NICE guidance does not mention genetic testing to see whether men with prostate cancer and BRCA2 defects can benefit from PARP inhibitors.
Why is the UK so far behind on this?